A5033429911- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Glycosylation and Glycoproteins Research
- Chromatography in Natural Products
- Phytochemical Studies and Bioactivities
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Cell Adhesion Molecules Research
- Caveolin-1 and cellular processes
- Brain Metastases and Treatment
- Bioactive natural compounds
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Flavonoids in Medical Research
- Peptidase Inhibition and Analysis
- Nanoplatforms for cancer theranostics
- Chronic Lymphocytic Leukemia Research
- Gastric Cancer Management and Outcomes
- CAR-T cell therapy research
- Proteoglycans and glycosaminoglycans research
- Lung Cancer Treatments and Mutations
- Esophageal Cancer Research and Treatment
- Nutrition and Health in Aging
- Balance, Gait, and Falls Prevention
- Frailty in Older Adults
Eisai (Japan)
2023-2024
Sapporo Medical University
2014
Abstract Purpose: E7389-LF is a liposomal formulation of the microtubule dynamics inhibitor eribulin and has shown preliminary efficacy in treatment gastric cancer. Study 120, phase Ib/II open-label study, assessed safety combination with nivolumab, programmed cell death (PD)-1 inhibitor. This report focuses on cancer cohort within expansion phase. Patients Methods: Eligible patients had unresectable, measurable cancer, progression following platinum drug plus fluoropyrimidine (1L),...
Background: A cancer survivor is defined as anyone who has been diagnosed with cancer, from the time of diagnosis through rest their life. The purpose this study was to examine whether physical functions, health-related outcomes, nutritional status and blood markers in community-dwelling survivors aged 75 years older are different those do not have Materials Methods: Two hundred seventy-five participants were asked by physicians, nurses, therapists, questions regarding history a face-to-face...
To determine a recommended dose of liposomal eribulin (E7389-LF) in combination with nivolumab patients advanced solid tumors, and to evaluate the safety, efficacy, pharmacokinetics, biomarker impact this regimen.Japanese advanced, nonresectable, or recurrent tumors no existing alternative standard/effective therapy (except monotherapy) were assigned either E7389-LF 1.7 mg/m2 plus 360 mg every 3 weeks, 2.1 1.1 240 2 1.4 weeks. Primary objectives safety/tolerability each cohort phase II...
<p>Supplementary Fig S2. Absolute neutrophil counts in patients who received prophylactic pegGCSF (A) and did not receive peg-GCSF (B), by visit</p>
<div>AbstractPurpose:<p>E7389-LF is a liposomal formulation of the microtubule dynamics inhibitor eribulin and has shown preliminary efficacy in treatment gastric cancer. Study 120, phase Ib/II open-label study, assessed safety E7389-LF combination with nivolumab, programmed cell death (PD)-1 inhibitor. This report focuses on cancer cohort within expansion phase.</p>Patients Methods:<p>Eligible patients had unresectable, measurable cancer, progression following...
<p>Supplementary Fig S3. Percent change in biomarkers at C1D8 (A) and C2D8 (B), pharmacodynamic changes plasma from C1D1 (C), dichotomized analysis of biomarker levels PFS (D)</p>
<p>Supplementary Fig S1. Patient dosing and responses over time (A) anticancer medication received during follow-up (B)</p>
<div>AbstractPurpose:<p>E7389-LF is a liposomal formulation of the microtubule dynamics inhibitor eribulin and has shown preliminary efficacy in treatment gastric cancer. Study 120, phase Ib/II open-label study, assessed safety E7389-LF combination with nivolumab, programmed cell death (PD)-1 inhibitor. This report focuses on cancer cohort within expansion phase.</p>Patients Methods:<p>Eligible patients had unresectable, measurable cancer, progression following...
<p>Supplementary Fig S1. Patient dosing and responses over time (A) anticancer medication received during follow-up (B)</p>
<p>Supplementary Fig S2. Absolute neutrophil counts in patients who received prophylactic pegGCSF (A) and did not receive peg-GCSF (B), by visit</p>
<p>Supplementary Fig S3. Percent change in biomarkers at C1D8 (A) and C2D8 (B), pharmacodynamic changes plasma from C1D1 (C), dichotomized analysis of biomarker levels PFS (D)</p>
This study examined the use of hip walking (HW) distance test as a physical performance parameter, and investigated association between HW strength, balance, gait speed in elderly. The involved 106 community-dwelling elderly individuals (mean age 75.4 years). Participants performed following tests: test, functional reach (FRT), tests for knee extensor trunk extensor, flexor 5 m maximum speed. For participants were asked to move forward fast possible from starting position with legs stretched...
337 Background: E7389-LF is a liposomal formulation of the microtubule dynamics inhibitor, eribulin. Treatment with plus programmed cell death 1 inhibitor nivolumab may result in an increased antitumor effect through vascular remodeling. The phase 1b part open-label Study 120 assessed dosing and safety combined patients (pts) solid tumors; 2 efficacy expansion cohorts, including esophageal cancer (EGC) cohort. Methods: For EGC cohort 120, pts were required to have unresectable, measurable...
339 Background: Due to a lack of efficacy and long-term survival seen in previously-studied therapies, new therapies for pretreated advanced GC are warranted. E7389-LF is formulation that uses liposomes encapsulate eribulin; this anticipated improve eribulin concentration tumor tissues. nivolumab have both shown as monotherapy GC. may also synergize well with PD-1 inhibitors by acting cytotoxic therapy modulating the microenvironment. Methods: Patients (pts) unresectable measurable GC,...